title: fMLP-induced CD11b/CD18 upregulation on neutrophils from patients with non-Hodgkin's lymphomas treated with recombinant human granulocyte colony-stimulating factor.
abstract: The effects of rhG-CSF administration on fMLP-induced neutrophil CD11b and CD18 upregulation were studied in nine patients suffering from intermediate and high grade non-Hodgkin's lymphomas. Blood samples were obtained before recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration and 24 hrs after rhGSF interruption. The growth factor was administered subcutaneously for five days in a dosage of 5 microg/Kg/day. Nine normal subjects were studied as controls. Five patients showed an impaired baseline CD11b and CD18 upregulation, which was corrected by rhG-CSF therapy. Four patients showed a normal baseline CD11b and CD18 upregulation, but this function was reduced by rhG-CSF therapy. All patients showed a normal baseline fMLP-induced luminol-enhanced chemiluminiscence and significantly increased chemiluminescence values after rhG-CSF administration. We conclude that, while in some patients rhg-CSF is able to improve neutrophil CD11b and CD18 upregulation in response to chemotactic agents, in other patients a decrease of this function can occur, maybe due to a relative immaturity of the circulating neutrophils induced by rhG-CSF.
authors.affiliation: Department of Oncology, 1st Medical Clinic, University of Pisa, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Carulli
authors.forename: A
authors.initials: A
authors.lastname: Azzarà
authors.forename: S
authors.initials: S
authors.lastname: Minnucci
authors.forename: C
authors.initials: C
authors.lastname: Angiolini
authors.forename: S
authors.initials: S
authors.lastname: Sbrana
authors.forename: F
authors.initials: F
authors.lastname: Ambrogi
mesh_terms: D000328:Adult; D000368:Aged; D018821:CD18 Antigens / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000188:drug therapy*; D016177:Macrophage-1 Antigen / Q000096:biosynthesis* / Q000097:blood; D008297:Male; D008875:Middle Aged; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000627:therapeutic use*; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013268:Stimulation, Chemical; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D018821:CD18 Antigens; D016177:Macrophage-1 Antigen; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D009240:N-Formylmethionine Leucyl-Phenylalanine